Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Analysis of gene expression in EIF3F knockdown 22Rv1 prostate cancer cells

ABSTRACT: Total RNA was obtained from 22Rv1 cells with or without EIF3F interference to perform a High-throughput sequencing

ORGANISM(S): Homo sapiens

PROVIDER: GSE140526 | GEO | 2022/11/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The transcriptomes of 22RV1 and PC3 cells with or without DDX52 interference

Project description:Total RNA was obtained from 22RV1 or PC3 cells with or without DDX52 interference to perform a High-throughput sequencing

2023-04-01 | GSE171797 | GEO

The transcriptomes of PC3 cells with or without KLF16 interference

Project description:Total RNA was obtained from PC3 cells with or without KLF6 interference to perform a High-throughput sequencing

2020-02-26 | GSE138286 | GEO

The transcriptomes of PC3 cells with or without POH1 interference

Project description:Total RNA was obtained from PC3 cells with or without POH1 interference to perform a High-throughput sequencing

2021-09-25 | GSE120481 | GEO

Analysis of gene expression in USP16 knockdown PC3 prostate cancer cells

Project description:Total RNA was obtained from PC3 cells with or without USP16 knockdown to perform a High-throughput sequencing. In our study, USP16 is necessary for prostate cancer cell proliferation in vitro and in vivo. Therefore, we perform the RNA-seq to explore potential mechanisms of USP16 regulating cell growth.

2023-11-01 | GSE160818 | GEO

22RV1 prostate cancer cell line transfected with SPINK1 siRNA vs control siRNA

Project description:ETS gene fusions have been characterized in a majority of prostate cancers, however key molecular alterations in ETS negative cancers are unclear. Here we used an outlier meta-analysis (meta-COPA) to identify SPINK1 outlier-expression exclusively in a subset of ETS rearrangement negative cancers (~10% of total cases). We validated the mutual exclusivity of SPINK1 expression and ETS fusion status, demonstrated that SPINK1 outlier-expression can be detected non-invasively in urine and observed that SPINK1 outlier-expression is an independent predictor of biochemical recurrence after resection. We identified the aggressive 22RV1 cell line as a SPINK1 outlier-expression model, and demonstrate that SPINK1 knockdown in 22RV1 attenuates invasion, suggesting a functional role in ETS rearrangement negative prostate cancers. Keywords: Genetic Modification 22RV1 cells were infected with non-targeting siRNA or siRNA against SPINK1. For reported hybridizations, the reference channel is 22RV1 cells infected with non-targeting siRNA. Duplicate hybridizations were performed with duplicate dye flips, for a total of four arrays. Over and under-expressed signatures were generated by filtering to include only features with significant differential expression (PValueLogRatio < 0.01) in all hybridizations and Cy5/Cy3 ratios > or < 1 in all hybridizations.

2008-06-10 | E-GEOD-11132 | biostudies-arrayexpress

The transcriptomes of 22RV1 and PC3 cells with or without DDX52 interference

Project description:The transcriptomes of 22RV1 and PC3 cells with or without DDX52 interference

| PRJNA720929 | ENA

Gene expression profile of 22RV1 prostate cancer cells upon SPINK1 knockdown

Project description:Serine Peptidase Inhibitor, Kazal type 1 (SPINK1) overexpression represents the second-largest prostate cancer (PCa) subtype associated with increased risk of biochemical recurrence and poor prognosis. To determine the pathways regulated by SPINK1 in 22RV1 prostate cancer cells, we performed shRNA mediated knockdown of SPINK1 using lentiviral constructs. Scrambled shRNA was used as a control. pGIPZ constructs against SPINK1 (shSPINK1-1, shSPINK1-2, shSPINK1-3) and control shScrambled construct were purchased from Dharmacon.

2019-12-16 | GSE124345 | GEO

22RV1 prostate cancer cell line transfected with SPINK1 siRNA vs control siRNA

2008-06-10 | GSE11132 | GEO

Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment

Project description:The gene expression profiling between Control and Luteolin in 22Rv1

2022-02-20 | GSE126856 | GEO

Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment

Project description:The miRNA expression profiling between Control and Luteolin in 22Rv1

2021-08-30 | GSE120181 | GEO